Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

1. Novo Nordisk acquires rights to develop zaltenibart for rare disorders. 2. Omeros could earn up to $2.1 billion, boosting investor confidence. 3. Layoffs at Novo Nordisk might impact operational efficiency short-term. 4. Positive phase 2 data for zaltenibart enhances future market potential. 5. Transaction expected to close in Q4 2025, indicating long-term investment strategy.